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Summary. Background: In a previous study we found that
intracerebral infusion of argatroban, a specific thrombin
inhibitor, reduces brain edema and neurologic deficits in a C6
glioma model. Objectives: To examine the role of thrombin in
gliomas and whether systemic argatroban administration can
reduce glioma mass and neurologic deficits and extend survival
time in C6 and F98 gliomas. Methods: The presence of
thrombin in human glioblastoma samples and rat C6 glioma
cells (in vitro and in vivo) was assessed using immunohisto-
chemistry. The effect of thrombin on C6 cell proliferation
in vitro was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide assay. The role of thrombin
in vivo was assessed in rat C6 and F98 glioma cell models using
argatroban, a thrombin inhibitor. The effects of argatroban on
tumor mass, neurologic deficits and survival time were
investigated. Results: Thrombin immunoreactivity was found
in cultured rat C6 glioma cells and human glioblastomas.
Thrombin induced C6 cell proliferation in vitro. In C6 glioma,
argatroban reduced glioma mass (P < 0.05) and neurologic
deficits (P < 0.05) at day 9. In F98 glioma, argatroban pro-
longed survival time (P < 0.05). Conclusion: These results sug-
gest that thrombin plays an important role in glioma growth.
Thrombin may be a new therapeutic target for gliomas.
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Introduction
It has long been known that thrombin has a pivotal role in the
coagulation cascade. However, the discovery and cloning of a
series of thrombin receptors [1], has suggested that thrombin
has a wide range of potential actions. Several pieces of evidence
led us to examine whether thrombin might have a major role in
malignant gliomas. (A) In contrast to normal brain, the
vasculature of these tumors is typically highly permeable with
the potential for prothrombin entry from blood into tumor. (B)
Brain edema in and around gliomas contributes to the high
mortality (within months) of patients with malignant gliomas
by causing herniation-related death. Our previous studies
indicate that thrombin plays an important role in edema
formation after intracerebral hemorrhage [2,3]. (C) Thrombin
is a potent mitogen, which enhances the synthesis and secretion
of nerve growth factor in glial cells and stimulates astrocyte and
tumor cell proliferation [4,5]. (D) Angiogenesis is essential for
rapid glioma growth because of the need for oxygen and
metabolites. Although many factors regulate angiogenesis,
thrombin may play an important role [6].
In apreliminary study,we found that intracerebral infusionof
argatroban, a specific thrombin inhibitor, reduces brain edema
and neurologic deficits in a rat C6 gliomamodel [7]. The current
experiments expand on this initial finding and specifically
determine whether thrombin is expressed in human glioblasto-
masand inratgliomacells in vivoand invitro, toexaminewhether
thrombin canmodulateC6 cell proliferation in vitro andwhether
thrombin inhibition affects tumor mass, tumor-induced behavi-
oral deficits and survival time in rat C6 and F98 gliomamodels.
Materials and methods
This study was in six parts. The first part determined whether
rat C6 and F98 glioma cells express thrombin in culture using
immunohistochemistry. The second part examined whether
human glioblastoma cells also express thrombin, again using
immunohistochemistry. The third part examined whether
thrombin can modulate C6 cell proliferation in vitro. The
fourth part tested whether thrombin can increase vascular
endothelial growth factor (VEGF) levels in vitro. The fifth part
examined whether systemic use of argatroban reduces tumor
mass and neurologic deficits in C6 glioma model. The last part
examined whether argatroban could prolong survival time in
F98 glioma model. Argatroban is a small molecular weight
(MW 508.7), direct thrombin inhibitor that inhibits both free
and fibrin-bound thrombin [8].
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Cell culture
Rat C6 (passage number 36–42) and F98 (passage numbers
9–11) glioma cell lines were obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA). C6 glioma
cells were grown at 37 C in air with 5% CO2 in Ham’s F-10
medium with 2.5% fetal bovine serum and 15% horse serum.
F98 glioma cells were obtained from ATCC and grown in
DMEM (ATCC) medium with 10% fetal bovine serum at
37 C in air with 5% CO2. Cells were maintained in a
monolayer culture.
Human glioma specimens
Surgical glioblastoma specimens (n ¼ 10) were obtained from
theDepartment ofNeurosurgery at theUniversity ofMichigan.
The protocol was approved by the Institutional Review Boards
at the University of Michigan. The specimens were frozen in
liquid nitrogen and stored at )80 C. Frozen sections (18 lm
thick) were taken on a cryostat for immunohistochemistry.
Cell proliferation in vitro
C6 glioma cells were cultured in 96-well plates at a cell density
of 5 · 103 cells per well. Cells were incubated in serum-free
medium for 24 h and then different doses of rat thrombin (0,
0.1, 0.25, 0.5, 1.0 and 2.5 U mL)1; Sigma, St Louis,MO,USA)
with or without argatroban (10 lM; GlaxoSmithKline,
Research Triangle, NC, USA) were added to the cell culture.
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide (MTT) assay [9] was performed 48 h later. Metabolically
active cells can change yellow tetrazolium salt MTT to indigo-
blue formazan. For the assay, MTT (5 mg mL)1, 25 lL per
200 lLmedium) was filtered, added to the wells and incubated
at 37 C for 4 h.Mediumwas removed gently using a 21-gauge
needle and 200 lLdimethyl sulfoxide was added. After 10 min,
the optical density was measured on a microplate reader at
540 nm with a reference wavelength of 630 nm. All in vitro
studies were repeated three times.
Animal preparation and the C6 and F98 glioma models
The protocols in this study were approved by the University of
Michigan Committee on the Use and Care of Animals. Adult
male Fischer 344 rats (200–225 g; Charles River Laboratories,
Portage, MI, USA) were anesthetized with pentobarbital
(50 mg kg)1, i.p.). Aseptic precautions were utilized in all
surgical procedures. After anesthesia was achieved, a poly-
ethylene catheter (PE-50) was inserted into the right femoral
artery in order to monitor arterial blood pressure and to obtain
blood for analysis of blood gases, blood pH, hematocrit, and
blood glucose concentration. They were then placed in a Kopf
stereotaxic frame. Body temperature was maintained at
37 ± 1 C using a rectal temperature probe and a feedback
regulator. A small burr hole was drilled in the skull overlying
the right caudate nucleus. The tip of a 26-gauge stainless steel
cannula was then lowered into the right caudate (0.2 mm
anterior, 5.5 mm ventral, 3.5 mm lateral to the bregma) and
1 · 106 C6 glioma cells were infused [10]. Sham animal had
only a needle insertion.
Alzet osmotic minipump implantation and argatroban
treatment
To examine whether thrombin contributed to brain edema
formation, glioma growth, glioma-related neurologic deficits
and survival time, animals were treated with argatroban, a
thrombin inhibitor. At the time of C6 or F98 glioma cell
implantation, rats were implanted intraperitoneally with an
osmotic minipump (Alzet, Cupertino, CA, USA). The pump
was preloaded with argatroban (60 mg mL)1 and delivers
5 lL h)1) or vehicle.
Immunohistochemistry
Immunohistochemistry was performed as previously described
[11]. Briefly, rats (n ¼ 3) were reanesthetized and were perfused
with 4% paraformaldehyde in 0.1 M phosphate-buffered saline
(pH 7.4). The brains were removed and kept in 4% parafor-
maldehyde for 12 h, then immersed in 25% sucrose for
3–4 days at 4 C. After embedding in the mixture of 25%
sucrose and OCT, 18-lm sections were taken on a cryostat.
The avidin–biotin complex technique was used in the staining
and hematoxylin was used for counter staining. The primary
antibody was sheep anti-human thrombin IgG (1:400 dilution;
Affinity Biologicals Inc., Ancaster, Canada). The sheep anti-
human thrombin IgG is raised against inactivated human
alpha-thrombin and reacts with human, rat and mouse
thrombin. Normal sheep IgG was used as a negative control.
Enzyme-linked immunosorbent assay (ELISA)
C6 glioma cells were cultured in 96-well plates at a cell density
of 5 · 104 cells per well. Cells were incubated in serum-free
medium for 24 h and then different doses of thrombin (0, 0.25
and 0.5 U mL)1; Sigma) were added to the cell culture. VEGF
levels in the supernatant were measured at 24 h after thrombin
stimulation with an ELISA kit (R & D systems). Data were
expressed as pg mL)1 supernatant.
Reverse transcription-polymerase chain reaction (RT-PCR)
At 9 days after C6 cell implantation or sham operation,
animals were reanesthetized with pentobarbital (60 mg kg)1,
i.p.) and killed by decapitation. C6 and F98 glioma cells were
also grown in vitro. The C6 gliomas and glioma cells were
sampled for RT-PCR [12]. Total RNA was extracted with
Trizol reagent (Gibco BRL, Grand Island, NY, USA), 1-lg
RNA was digested with deoxyribonuclease (DNaseI, Ampli-
fication Grade, Gibco BRL). cDNA was synthesized by RT
using the digested 1 lg RNA (11 lL) with 14 lL of reaction
buffer (Perkin-Elmer, Foster City, CA, USA) containing
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dNTP (dATP, dCTP, dGTP and dTTP), 25 mM MgCl2, 10x
PCRbuffer II, RandomHexamer Primer, RNase inhibitor and
MuLV reverse transcriptase. The reaction was performed at
42 C for 30 min and terminated at 99 C for 5 min. Diethyl
pyrocarbonate water (75 lL) was added to dilute the cDNA to
100 lL and stored at )20 C until use.
Polymerase chain reaction was performed with 15 lL of the
reverse transcriptase reaction mixture (Perkin-Elmer) contain-
ing 25 mM MgCl2, dNTP, 10x PCR buffer II and AmpliTaq
DNA Polymerase in a final volume of 50 lL. The rat
prothrombin primers (NIH GenBank database) corresponded
to nucleotides 1674–1692 (sense primer, 5¢-TCCTCGCTTGG-
TGTCATTC-3¢) and nucleotides 1349–1367 (antisense primer,
5¢-CAAGCACTCCAGAACCAGA-3¢). Rat GAPDH prim-
ers (5¢-CTCAGTGTAGCCCAGGATGC-3¢, 5¢-ACCACCA-
TGGAGAAGGCTGG-3¢) were used to amplify GAPDH
mRNA, a housekeeping gene used as a control. Amplification
was performed in a DNA thermal cycler (MJ Research,
Watertown, MO, USA). Samples were subjected to 30 cycles
(94 C, 30 s; 55 C, 30 s; and 72 C, 1 min). PCR production
was analyzed by the use of electrophoresis on a 1%agarose gel.
Gels were visualized with ethidium bromide staining and
ultraviolet transillumination. Photographs were taken with
black and white film (Polaroid Corp., Waltham, MA, USA)
and analyzed using NIH image 1.62.
Tumor mass
We used the weight difference between the ipsilateral (tumor
side) and contralateral hemisphere to estimate the tumor mass.
Behavioral tests
Animals were placed in a cylindrical enclosure to record
preferential use of the non-impaired forelimb for weight
shifting movements during spontaneous vertical exploration.
The percentage independent use of the non-impaired forelimb
(ipsilateral to the tumor), the percentage independent use of the
contralateral forelimb, and the percentage use of both
forelimbs together in rapid succession for stepping movements
along the walls of the cylinder were assessed. A single score was
then used to reflect forelimb use asymmetry: percentage
ipsilateral limb use minus percentage contralateral limb use
(low score ¼ better function). In addition, a vibrissae-stimula-
ted forelimb placing test (10 trials per side for each rat) was
used to examine sensorimotor/proprioceptive capacity (high
score ¼ better function) [13]. All behavior was scored by
experimenters who were blind to both neurologic and treat-
ment conditions. These tests are highly correlatedwith extent of
striatal injury without being influenced by repeated testing.
Statistics
The results are reported as mean ± S.D. Data were analyzed
by analysis of variance (ANOVA) followed by Scheffe’s post hoc
test, Student’s t-test, Mann–Whitney U-rank test or Trend
Peto–Peto–Wilcoxon test. Differences were considered signifi-
cant at the P < 0.05 level.
Results
Thrombin immunoreactivities were detected in culturedC6 and
F98 glioma cells in vitro (Fig. 1A,B). Similarly, thrombin was
detected in human glioblastomas. Figure 1C shows a repre-
sentative example of the 10 glioblastomas sampled.
To examine whether thrombin would affect C6 glioma cell
proliferation in vitro, cells were exposed to thrombin at a
concentration range of 0–2.5 U mL)1 (higher concentrations
are cytotoxic [14]) and proliferation assessed with an MTT
assay. Thrombin induced proliferation at 0.1 and 0.25 U mL)1,
but not at higher concentrations (Fig. 2A). The thrombin-
induced proliferation was blocked by addition of argatroban, a
thrombin inhibitor (Fig. 2B).
Thrombin can stimulate VEGF production in vitro
(P < 0.05). The VEGF levels in the supernatant of C6 cell
culture were 101 ± 16, 151 ± 21 and 136 ± 21 pg mL)1 at





Fig. 1. The presence of thrombin immunoreactivity in cultured C6 (A)
and F98 (B) glioma cells and a human glioblastoma tissue sample (C).
Arrows indicate thrombin-positive cells. Scale bar ¼ 20 lm.
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In this C6 gliomamodel, thrombinwas detected in the tumor
using an antibody to thrombin (Fig. 3A,B). Thrombin immu-
noreactivity in glioma was much greater than that found in the
contralateral hemisphere (Fig. 3C). Thrombin-positive cells
were localized in the tumor center and the tumor edge. In the
glioma center, most of the tumor cells are thrombin positive. In
addition, prothrombin mRNA was detected in C6 and F98
glioma cells in culture (Fig. 4A). Prothrombin mRNA levels
increased in the C6 glioma (1732 ± 93 pixels vs. 970 ± 133
pixels in the sham, P < 0.05, Fig. 4B).
We used the weight difference between the ipsilateral (tumor
side) and the contralateral hemisphere to estimate the tumor
mass. Argatroban (0.3 mg h)1 per rat) reduced C6 glioma
mass at day 9 (43 ± 31 mg vs. 80 ± 35 mg in the vehicle
group, n ¼ 8,P < 0.05). Argatroban treatment also improved
C6 glioma-related neurologic deficits including forelimb use
asymmetry and forelimb placing (Fig. 5).
Rats were examined every day and started to die from
10 days after F98 glioma cell implantation. Argatroban
prolonged survival time in F98 glioma model (18 ± 3 days
vs. 14 ± 4 days in the vehicle group, n ¼ 20,P < 0.05, Trend










0 0.1 0.25 0.5 1.0 2.5 0 0.25










Fig. 2. Thrombin stimulation of C6 cell proliferation as assessed by MTT assay. (A) C6 glioma cells were exposed to different doses of thrombin (0, 0.1,
0.25, 0.5, 1.0 and 2.5 U mL)1) and the MTT assay was performed 48 h later. Values are mean ± SD (n ¼ 9). indicates a significant difference from
control (no thrombin) at theP < 0.01 level. (B) C6 glioma cells were treated with either vehicle, argatroban (10 lM), thrombin (0.25 U mL)1) or thrombin
(0.25 U mL)1) plus argatroban (10 lM), cell growth was assayed by MTT 48 h later. Values are mean ± SD (n ¼ 9). # indicates a significant difference
between the vehicle and argatroban-treated groups at the P < 0.01 level.
A B C
Fig. 3. Immunohistochemistry for thrombin in C6 gliomas. (A) Center of the C6 cell glioma, (B) the edge of the glioma and (C) the contralateral
hemisphere. Arrows indicate thrombin-positive cells. Scale bar ¼ 20 lm.
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B
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Fig. 4. (A) ProthrombinmRNA levels measured byRT-PCR in C6 (lanes
1 and 2) and F98 glioma cells in culture. (B) Prothrombin mRNA levels in
three gliomas 9 days after intracerebral infusion of C6 glioma cells (lanes
1–3) and in the ipsilateral basal ganglia 9 days after sham operation (lanes
4–6).
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Discussion
This study demonstrates that thrombin is expressed in rat C6,
F98 glioma cells and human glioblastomas, that thrombin can
induce proliferation of C6 glioma cells in vitro and that systemic
use of argatroban, a thrombin inhibitor, can reduce tumor
mass and behavioral deficits in a C6 glioma model in the rat.
Argatroban also improved F98 glioma-induced behavioral
deficits and prolonged survival time in that glioma model.
Together, this suggests that thrombin could be a therapeutic
target in gliomas. This adds to a growing body of evidence that
thrombin can have profound non-hemostatic effects in the
brain that are important in brain injury and disease [1,15].
The presence of thrombin in the C6 gliomamodel in vivo and
in the human glioblastoma samples could be derived from
prothrombin entering the tumor from the systemic circulation
via a disrupted blood–tumor barrier, or it may be derived from
the tumor itself or a combination of both. As yet it is impossible
to determine the significance of these potential sources.
However, the fact that prothrombin mRNA and thrombin
were detected in C6 and F98 cells in culture, and prothrombin
mRNA levels were increased in C6 gliomas indicate that tumor
cell-derived thrombin is at least a component. This suggestion
is supported by evidence that the brain, including astrocytes,
produces prothrombin mRNA [16]. It should be noted,
however, that non-cancerous cells within the tumor might
contribute to the increase of prothrombin mRNA levels in the
C6 glioma in vivo. Thus, macrophages in gliomas commonly
produce prothrombin and express the clotting factors necessary
for thrombin production [17]. Clotting factors other than
prothrombin have also been identified in brain parenchyma
[15].
The current study demonstrates that thrombin can increase
C6 cell proliferation in vitro. There is other evidence supporting
that thrombin can regulate cell proliferation. Thrombin
enhances the synthesis and secretion of nerve growth factor
in glial cells [4] and stimulates astrocyte proliferation [5]. In
addition, thrombin may act as a growth factor for tumor cells
[18] and induces proliferative response in T-47D mammary
tumor cells [19]. In T98G and TM-1 human glioma cells,
thrombin also induced proliferation. This mitogenic effect was
abolished by hirudin, a thrombin inhibitor [20]. In our study,
the effect might have been blocked by argatroban, another
thrombin inhibitor.
Although the primary role of thrombin in hemostasis is
through cleaving fibrinogen to fibrin, other important cellular
activities of thrombin may be related to thrombin receptor
activation. Three protease-activated receptors (PARs), PAR-1,
PAR-3 and PAR-4, have been identified as thrombin receptors
[1]. Thrombin receptors are activated by proteolytic cleavage
rather than by ligand binding and thrombin receptor-activated
peptides are able to mimic many cellular activities of thrombin.
Recent studies indicate that PARs mediate some of the
pathophysiological effects of thrombin. For example, PAR-1
activation by thrombin receptor activating peptide results in
angiogenesis [6]. Thrombin receptors have been found in many
types of tumor cells [21] including rat C6 cells ([22] andY. Hua,
R.F. Keep, G. Xi, unpublished data).Whether the proliferative
effects of thrombin on C6 cells are PAR mediated deserves
further investigation. It is also possible that the absence of a
















































Fig. 5. The effects of argatroban on neurologic deficits in the C6 glioma
model. Forelimb placing score (A) and forelimb use asymmetry (B) in rats
after intracerebral implantation of C6 glioma cells. The rats were treated
with argatroban or vehicle. Values are mean ± SD, n ¼ 9–10, *P < 0.05
vs. other groups, **P < 0.05 vs. glioma + argatroban. Mann–Whitney
U-rank test. For the forelimb placing test, a score of 100% indicates no



















Fig. 6. The effect of argatroban on rat survival time after F98 glioma
implantation.
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reflect the activation of different types of PAR receptor. There
has been debate about whether or not thrombin in gliomas is
enzymatically active based on the cleavage of fibrinogen [23].
Our findings on the effects of argatroban in vivo and in vitro
suggest that gliomas have functionally active thrombin but do
not address the issue of whether this involves thrombin
receptor-mediated or fibrinogen cleavage mechanisms.
Evidence for a potentially important role for thrombin in
gliomas was also found in vivo. Argatroban reduced tumor
mass, neurologic deficits and prolonged survival time. Arg-
atroban was chosen as the thrombin inhibitor in this study. It is
a small molecule (MW 508.7) and a direct thrombin inhibitor
binding to the catalytic site of the thrombin molecule.
Argatroban is an effective inhibitor of thrombin both bound
to fibrin and thrombin free in solution [8,24]. The effect of
thrombin on tumor mass may result from a direct effect on
tumor cell proliferation, as described in vitro. As ourmeasure of
tumor mass includes edema, the effect of argatroban on mass
may also reflect reduced edema formation. Another possibility
is thrombin may increase tumor mass by affecting blood vessel
proliferation as thrombin is a potent promoter of angiogenesis
[25].
Other experimental data suggest a role for coagulation
and fibrinolysis systems in tumor development, progression
and metastasis [23,26]. Clinical data also suggest that targeting
the coagulation system might influence the course of malig-
nant disease. The anticoagulant drug warfarin prolongs the
length of survival of patients with small cell lung cancer.
Heparin has a benefit in patients with several types of cancer
[27]. Our results suggest that drugs directly targeting thrombin
may have similar actions and that warfarin and heparinmay be
having their effects by reducing thrombin production or
activity.
In this study, argatroban reduced neurologic deficits in the
glioma model. Traditional preclinical investigations of brain
tumor therapies have focused primarily on inhibiting tumor cell
proliferation or survival with little regard to behavioral
assessment. However, in clinical trials brain function has been
an essential index of treatment benefit.Moreover, it seems clear
from the literature on brain injury and recovery of function
that mechanisms of neural plasticity needed for optimal
behavioral outcome in a brain compromised by tumor growth
might be vulnerable to some tumor treatments, including
irradiation, pro-apoptotic drugs, or agents that adversely affect
angiogenesis, mitosis or neurotrophic factor activity [7,28,29].
A model that includes sensitive functional outcome measures
would appear to represent a significant advantage in brain
tumor research.
The current study provides evidence that thrombin could be
a therapeutic target for malignant gliomas. It does not address
the question of whether thrombin plays a role in other forms of
brain tumor, i.e. is it specific for gliomas or does thrombin
stimulate tumor growth in, for example, low-grade astrocyto-
mas? But, in relation to this point, there is evidence that the
effect of thrombin is not confined to gliomas from examination
of tumors outside of the brain [30]. In particular, the effects of
thrombin on angiogenesis suggest that it may affect growth in a
variety of solid tumors which depend on the formation of new
blood vessels [6,26,30].
In summary, our results have shown that anti-thrombin
treatment with argatroban reduces tumor mass, improves
neurologic scores and prolongs survival time. Clarification of
the role of thrombin in glioma proliferation, angiogenesis and
edema formation should help to develop new therapeutic
strategies for glioma treatment.
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